Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

Company Overview

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $1.49 to $1.63
• 50-Day Range: $1.48 to $3.63
• 52-Week Range: $1.38 to $8.19
• Volume: 606,013 shs
• Average Volume: 382,294 shs
• Market Capitalization: $70.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

Werewolf Therapeutics Stock Analysis - MarketRank™

Werewolf Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 260th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Werewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Werewolf Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Werewolf Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Werewolf Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Werewolf Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.76% of the float of Werewolf Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Werewolf Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Werewolf Therapeutics has recently decreased by 6.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Werewolf Therapeutics does not currently pay a dividend.

Dividend Growth

Werewolf Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.76% of the float of Werewolf Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Werewolf Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Werewolf Therapeutics has recently decreased by 6.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Werewolf Therapeutics has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for HOWL on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

10 people have added Werewolf Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.10% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.84% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HOWL Stock Analysis - Frequently Asked Questions

How have HOWL shares performed this year?

Werewolf Therapeutics' stock was trading at $3.86 at the beginning of the year. Since then, HOWL stock has decreased by 58.8% and is now trading at $1.59.
View the best growth stocks for 2024 here.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 578.80% and a negative trailing twelve-month return on equity of 58.83%.

When did Werewolf Therapeutics IPO?

Werewolf Therapeutics (HOWL) raised $101 million in an IPO on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' top institutional shareholders include PFM Health Sciences LP (7.63%), Geode Capital Management LLC (1.54%), State Street Corp (1.07%) and Point72 Asset Management L.P. (0.25%).
View institutional ownership trends.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Werewolf Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Werewolf Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOWL
• CUSIP: N/A
• CIK: 1785530
• Web: werewolftx.com
• Phone: 617-952-0555
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +654.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,370,000.00
• Net Margins: -578.80%
• Pretax Margin: -1,834.55%
• Return on Equity: -58.83%
• Return on Assets: -38.45%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 10.10
• Quick Ratio: 10.10

Sales & Book Value

• Annual Sales: $3.39 million
• Price / Sales: 20.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.08 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 44,563,000
• Free Float: 35,160,000
• Market Cap: $70.86 million
• Optionable: Optionable
• Beta: 0.30